Department of Ophthalmology, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India.
Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India.
Indian J Ophthalmol. 2022 May;70(5):1466-1474. doi: 10.4103/ijo.IJO_1595_21.
Corneal collagen cross-linking (CXL) is an effective treatment for arresting progression in patients with keratoconus. CXL was approved by United States Food and Drug Administration for the treatment of progressive keratoconus in 2016. It is a relatively safe procedure with a low complication rate. As this approach becomes more popular, it is paramount to be familiar with the potential complications associated with the procedure and its management. This article aims to report and review the complications of CXL for the treatment of keratoconus and post-LASIK ectasia.
角膜胶原交联术（CXL）是治疗圆锥角膜进展的有效方法。2016 年，美国食品和药物管理局（FDA）批准 CXL 用于治疗进展性圆锥角膜。该方法相对安全，并发症发生率低。随着该方法的普及，熟悉与该方法相关的潜在并发症及其处理方法至关重要。本文旨在报告和回顾 CXL 治疗圆锥角膜和 LASIK 后扩张性角膜病变的并发症。
Zotero 插件
